Quarterly ResultMay 11, 2026, 07:03 AM
Lexeo Therapeutics Submits LX2006 Pivotal Trial Protocol; Cash Runway into 2028
AI Summary
Lexeo Therapeutics provided business updates and Q1 2026 financial results. The company submitted the SUNRISE-FA 2 pivotal trial protocol and statistical analysis plan for LX2006 to the FDA, with interim Phase I/II data showing statistically significant improvements in Friedreich Ataxia. LX2006 remains well tolerated. The company also reported positive interim data for LX2020 and preclinical data for LX2022. Lexeo ended Q1 2026 with $227.6 million in cash, cash equivalents, and investments, extending its operational runway into 2028. Net loss for the quarter significantly decreased to $20.2 million.
Key Highlights
- Submitted SUNRISE-FA 2 pivotal trial protocol and SAP for LX2006 to FDA in Q1 2026.
- LX2006 Phase I/II interim data show statistically significant improvement in mFARS scores (p=0.003).
- Cash, cash equivalents, and investments of $227.6 million provide operational runway into 2028.
- Net loss for Q1 2026 was $20.2 million, down from $32.7 million in Q1 2025.
- Research & Development expenses were $15.7 million in Q1 2026, down from $17.2 million YoY.
- General & Administrative expenses were $6.6 million in Q1 2026, down from $16.6 million YoY.
- Appointed Laura Sepp-Lorenzino, Ph.D. as an independent director to the Board.
- Anticipates FDA feedback on LX2006 protocol and initiation of SUNRISE-FA 2 trial in Q2 2026.